Guard Therapeutics International AB (publ)

DB:5LH0 Stock Report

Market Cap: €29.9m

Guard Therapeutics International Management

Management criteria checks 1/4

Guard Therapeutics International's CEO is Tobias Agervald, appointed in Jan 2019, has a tenure of 5.67 years. directly owns 0.21% of the company’s shares, worth €62.31K. The average tenure of the management team and the board of directors is 4 years and 2.5 years respectively.

Key information

Tobias Agervald

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.7yrs
CEO ownership0.2%
Management average tenure4yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tobias Agervald's remuneration changed compared to Guard Therapeutics International's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-SEK 79m

Mar 31 2024n/an/a

-SEK 88m

Dec 31 2023n/an/a

-SEK 113m

Sep 30 2023n/an/a

-SEK 137m

Jun 30 2023n/an/a

-SEK 146m

Mar 31 2023n/an/a

-SEK 134m

Dec 31 2022SEK 5mSEK 2m

-SEK 113m

Sep 30 2022n/an/a

-SEK 95m

Jun 30 2022n/an/a

-SEK 97m

Mar 31 2022n/an/a

-SEK 88m

Dec 31 2021SEK 4mSEK 2m

-SEK 82m

Sep 30 2021n/an/a

-SEK 69m

Jun 30 2021n/an/a

-SEK 47m

Mar 31 2021n/an/a

-SEK 44m

Dec 31 2020SEK 3mSEK 1m

-SEK 40m

Sep 30 2020n/an/a

-SEK 43m

Jun 30 2020n/an/a

-SEK 39m

Mar 31 2020n/an/a

-SEK 41m

Dec 31 2019SEK 4mSEK 1m

-SEK 45m

Compensation vs Market: Insufficient data to establish whether Tobias's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Tobias's compensation has increased whilst the company is unprofitable.

CEO

Tobias Agervald (48 yo)

5.7yrs

Tenure

SEK 5,230,000

Compensation

Mr. Tobias Larsson Agervald has been Chief Executive Officer at Guard Therapeutics International AB (publ) (formerly known as A1M Pharma AB (publ))since January 15, 2019 and served as its Chief Medical Off...

Leadership Team

NamePositionTenureCompensationOwnership
Tobias Agervald
Chief Executive Officer5.7yrsSEK 5.23m0.21%
SEK 62.3k
Karin Botha
Chief Financial Officer4yrsno data0.024%
SEK 7.1k
Magnus Gram
C.S.O5.3yrsno datano data
Peter Gilmour
Head of Preclinical Science4.1yrsno datano data
Sara Thuresson
Head of Clinical Operations3.3yrsno data0.016%
SEK 4.8k
Michael Reusch
Chief Medical Officer2.7yrsno datano data
Torbjorn Larsson
Head of Chemistry2.3yrsno data0.0017%
SEK 496.0

4.0yrs

Average Tenure

51yo

Average Age

Experienced Management: 5LH0's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Johan Bygge
Independent Chairman of the board3.3yrsSEK 271.00k0.052%
SEK 15.6k
Khatereh Ahmadi
Directorless than a yearno datano data
Michael Brownstein
Member of Scientific Boardno datano datano data
Goran Forsberg
Non-Executive Independent Director5.3yrsSEK 162.00k0.011%
SEK 3.4k
Fredrik Lehmann
Non-Executive Independent Director1.8yrsSEK 7.00kno data
Gunvor Ordeberg
Member of Scientific Boardno datano datano data
Anthony Kettle
Member of Scientific Boardno datano datano data
Christopher Redman
Member of Scientific Boardno datano datano data
Henning Schneider
Member of Scientific Boardno datano datano data
Johannes Hulthe
Non-Executive Independent Director5.3yrsSEK 162.00k0.050%
SEK 14.9k
Hege Hellstrom
Directorless than a yearno datano data
József Balla
Member of Scientific Boardno datano datano data

2.5yrs

Average Tenure

59yo

Average Age

Experienced Board: 5LH0's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.